Search company, investor...

Predict your next investment

Angel Investor (Group)
lifescienceangels.com

Investments

144

Portfolio Exits

22

Funds

1

About Life Science Angels

Life Science Angels, Inc. (LSA) is an angel investment group focused solely on biotechnology and medical device companies. Since 2005, LSA has invested $26.5 million in 30 companies which have received an additional $500+ million on follow-on funding from VCs.

Headquarters Location

Palo Alto, California,

United States

Want to inform investors similar to Life Science Angels about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Expert Collections containing Life Science Angels

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Life Science Angels in 1 Expert Collection, including Synthetic Biology.

S

Synthetic Biology

382 items

Latest Life Science Angels News

InnoSIGN Completes Spin-Out from Philips with an $8M Series A Financing to Revolutionize Precision Medicine through its OncoSIGNal Pathway Activity Profiling Platform

Mar 22, 2022

Eindhoven, NETHERLANDS InnoSIGN utilizes its proprietary database with over 100,000 pathway activity profiles for drug development and diagnostics to predict patient response to targeted therapies Proceeds support additional clinical validation and US market launch WILMINGTON, Del. and EINDHOVEN, The Netherlands, March 22, 2022 (GLOBE NEWSWIRE) -- InnoSIGN, a precision medicine company, today announced that it raised an $8M Series A financing. Proceeds will be used to finance a spin-out from Royal Philips to form a standalone company centered upon the OncoSIGNal pathway activity profiling technology. Investors in the round include Casdin Capital, Life Science Angels, Thuja Capital and Brabant Development Agency. Philips owns a minority stake in the new company. InnoSIGN commercializes OncoSIGNal mRNA-based tests that measure the activity of signal transduction pathways in cancer and immune cells to predict how patients will respond to targeted drugs. The OncoSIGNal qPCR 7 pathway test is available for Research-Use-Only, enabling research labs to run the test on conventional PCR machines in combination with the OncoSIGNal cloud-based data analysis software. The investment enables InnoSIGN to implement its ambitious growth plans by leveraging a first mover advantage to complete further clinical validation studies and launch in the US market. InnoSIGN Inc. a US-based company, will maintain its leading R&D facility located at the High Tech Campus in Eindhoven, The Netherlands. “I am excited with the investment and sponsorship from this strong syndicate of US and Dutch investors,” said Paul van de Wiel, CEO and co-founder of InnoSIGN. “This funding round will enable us to demonstrate the added value of OncoSIGNal compared to standard technologies for the better understanding of cell behavior, which is highly relevant to physicians when selecting the optimal personalized therapy for cancer patients.” “As the limitations of DNA sequencing and protein analysis have become clear during the last years, we believe InnoSIGN’s proprietary mRNA-based signaling pathway tests, database with pathway activity profiles, and advanced analytics software will drive the next breakthroughs in precision medicine, initially in oncology, and then in other autoimmune and infectious disease," said Allan May, chair of Life Science Angels and investor. OncoSIGNal was developed by scientists at Philips Research as a breakthrough technology for quantifying cell signaling pathway activity. Powerful proprietary software normalizes and translates mRNA levels transcribed from a suite of selected genes into activity scores of the relevant signal transduction pathways. OncoSIGNal utilizes its extensive database to gain insight into the signaling pathway profiles of the different cancer and immune cells leading to deep understanding of the mechanisms of the disease and potentially new therapy options. “We are happy to be partnering with this consortium. InnoSIGN, as a stand-alone company, will be able to accelerate the development of OncoSIGNal tests which have the potential to make oncology diagnostics more efficient and precise, leading to better health outcomes,” says Henk van Houten, CTO and Head of Research of Philips. About InnoSIGN InnoSIGN commercializes its proprietary mRNA-based OncoSIGNal pathway activity profiling technology, revolutionizing precision medicine by obtaining more insight into the mechanisms of disease. OncoSIGNal is available for Research-Use-Only offered as qPCR tests for decentralized use and via its service testing facility in The Netherlands. InnoSIGN utilizes its extensive database with more than 100,000 pathway activity profiles to support diagnostics and drug development. For more information please contact Gwen Sülter at oncosignal@innosignbio.com

Life Science Angels Investments

144 Investments

Life Science Angels has made 144 investments. Their latest investment was in InnoSIGN as part of their Series A on March 3, 2022.

CBI Logo

Life Science Angels Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/22/2022

Series A

InnoSIGN

$8M

Yes

5

4/22/2021

Series A

Strategikon Pharma

Yes

1

12/10/2020

Series A

Astrocyte Pharmaceuticals

$6M

Yes

2

8/28/2020

Unattributed

Subscribe to see more

$99M

Subscribe to see more

10

1/16/2019

Series A - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/22/2022

4/22/2021

12/10/2020

8/28/2020

1/16/2019

Round

Series A

Series A

Series A

Unattributed

Series A - II

Company

InnoSIGN

Strategikon Pharma

Astrocyte Pharmaceuticals

Subscribe to see more

Subscribe to see more

Amount

$8M

$6M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

5

1

2

10

10

Life Science Angels Portfolio Exits

22 Portfolio Exits

Life Science Angels has 22 portfolio exits. Their latest portfolio exit was Amplyx Pharmaceuticals on April 28, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/28/2021

Acquired

$99M

8

8/13/2019

Acquired

$99M

1

8/2/2019

Acquired

$99M

3

6/13/2019

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

1/24/2019

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/28/2021

8/13/2019

8/2/2019

6/13/2019

1/24/2019

Exit

Acquired

Acquired

Acquired

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

8

1

3

10

10

Life Science Angels Fund History

1 Fund History

Life Science Angels has 1 fund, including Life Science Angels Side Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

6/14/2006

Life Science Angels Side Fund

Early-Stage Venture Capital

Closed

$1M

1

Closing Date

6/14/2006

Fund

Life Science Angels Side Fund

Fund Type

Early-Stage Venture Capital

Status

Closed

Amount

$1M

Sources

1

Life Science Angels Team

4 Team Members

Life Science Angels has 4 team members, including , .

Name

Work History

Title

Status

Allan W. May

Emergent Medical Partners

Founder

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Allan W. May

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Emergent Medical Partners

Title

Founder

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.